The role of bisphosphonates in breast and prostate cancers

Endocrine-Related Cancer

Volumn 11, Issue 2, 2004, Pages 207-224

  Brown, Janet E ^a   Neville Webbe, Helen ^a   Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETIDRONIC ACID; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; HYDROXYAPATITE; IBANDRONIC ACID; METHOTREXATE; MINODRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RISEDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; ZOLEDRONIC ACID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE MINERAL; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; LUNG NON SMALL CELL CANCER; MYALGIA; MYELOMA; NEPHROTOXICITY; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHYSICAL DISABILITY; PROSTATE CANCER; REHYDRATION; REVIEW; SOLID TUMOR; SPINAL CORD COMPRESSION; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 3042642209     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110207     Document Type: Review

References (124)

1. Amin D, Cornell SA, Gustafson SK, Needle, SJ, Ullrich JW, Bilder GE & Perrone MH 1992 Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. Journal of Lipid Research 33 1657-1663.
2. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group 2002 Anastrazole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359 2131-2139.
3. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R & Amiot M 1997 Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90 1649-1655.
4. Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F & Von Teichert JM 2001a A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91 144-154.
5. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A & Seaman JJ 2001b Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 1191-1200.
6. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR & Angeli A 2002 Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Journal of Urology 167 2361-2367.
7. Bilezikian JP 1999 Osteoporosis in men. Journal of Clinical Endocrinology and Metabolism 84 3431-3434.
8. Body J-J 2003 Effectiveness and cost of bisphosphonate therapy in tumour bone disease. Cancer 97 (Suppl 3) 859-865.
9. Body J-J, Lichinitser MR, Diehl IE et al. 1999. Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proceedings of the American Society of Clinical Oncology 18 575a.
10. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM & Clezardin P 2000 Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Research 60 2949-2954.
11. Brown JE, Thomson CS, Ellis SP, Gutcher S, Turner L, Purohit OP & Coleman RE 2003a Bone resorption predicts for skeletal complications in metastatic bone disease. British Journal of Cancer 89 2031-2037.
12. Brown J, Cook R, Coleman RE, Major PP, Lipton A, Zheng M, Hei Y & Seaman J 2003b The role of bone turnover markers in predicting clinical events in metastatic bone disease. Proceedings of the American Society of Clinical Oncology 22 Abstract 2969.
13. Bryden AA, Hoyland JA, Freemont AJ, Clarke NW & George NJ 2002 Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. British Journal of Cancer 86 322-325.
14. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR & Ahmed T 2000 Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. British Journal of Cancer 83 360-365.
15. Coleman RE 1998 Pamidronate disodium in the treatment and management of hypercalcaemia. Reviews in Contemporary Pharmacotherapy 9 147-164.
16. Coleman RE & Rubens RD 1987 The clinical course of bone metastases in breast cancer. British Journal of Cancer 55 61-66.
17. Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn KJ & Kanis J 1999 Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease. Annals of Oncology 10 311-316.
18. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G & Ford JM 1996 Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial. Journal of Clinical Oncology 14 2552-2559.
19. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S & Ettinger B 1998 Endogenous hormones and the risk of hip and vertebral fracture among older women. New England Journal of Medicine 339 733-738.
20. Daniell HW 1997 Osteoporosis after orchiectomy for prostate cancer. Journal of Urology 157 439-444.
21. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z & Stratte PT 2000 Progressive osteoporosis during androgen deprivation therapy for prostate cancer. Journal of Urology 163 181-186.
22. Dearnaley D, Sydes MR, Mason MD et al. 2003 Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PR05 trial 2003. Journal of the National Cancer Institute 95 1300-1311.
23. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P & Bremond A 1997 Bisphosphonate risedronate prevents bone loss in women with artifical menopause due to chemotherapy of breast cancer: a double blind placebo-controlled study. Journal of Clinical Oncology 15 955-962.
24. Denoyelle C, Hong L, Vannier J-P, Soria J & Soria C 2003 New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual Rho-A-dependent and independent effects. British Journal of Cancer 88 1631-1640.
25. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL & Bataille R 1999 Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. Journal of Bone and Mineral Research 14 2048-2056.
26. Diamond T, Campbell J, Bryant C & Lynch W 1998 The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma; longitudinal evaluation and response to intermittent cyclic tidronate therapy. Cancer 83 1561-1566.
27. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH & Lynch WJ 2001 The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomised, placebo-controlled cross over study. Cancer 92 1444-1450.
28. Diel IJ, Marschner N, Kindler M et al. 1998a Continuous oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proceedings of the American Society of Clinical Oncology 18 128a Abstract 488.
29. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M & Bastert G 1998b Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine 339 357-363.
30. Diel IJ, Solomayer E, Gollan C, Schutz F & Bastert G 2000 Bisphosphonates in the reduction of metastases in breast cancer - results of the extended follow-up of the first study population. Proceedings of the American Society of Clinical Oncology 20 314 Abstract 82a.
31. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH & Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. Journal of Pharmacology and Experimental Therapeutics 296 235-242.
32. Eastell R, Hannon RA, Cuzick J, Clack G & Adams JE 2002 Effect of anastrozole on bone density and bone turnover: results of the 'Arimidex' (anastrozole), tamoxifen alone or in combination (ATAC) trial bone sub-protocol. ASBMR.
33. Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L & Seppanen J 1992 Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. International Urology and Nephrology 24 159-166.
34. Eriksson S, Eriksson A, Stege R & Carlstrom K 1995 Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcified Tissue International 57 97-99.
35. Ernst DS, Tannock IF, Venner PM, Winquist L, Reyno H, Walker K, Ding C, Elliot W & Parulekar W 2002 Randomized placebo controlled trial of mitoxantrone/ prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proceedings of the American Society of Clinical Oncology 21 705 Abstract 177a.
36. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE & Delmas PD 2000 Markers of bone turnover for the management of patients with bone metastases from prostate cancer. British Journal of Cancer 82 858-864.
37. Gnant M, Hausmaninger H, Samonigg H et al. 2002 Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+/- zoledronate) as adjuvant treatment for hormone receptor premenopausal breast cancer: results of a randomised multicentre trial. Breast Cancer Research and Treatment 76 (Suppl 1) 11 Abstract S31.
38. Goss P, Grynpas M, Qi S & Hu H 2001 The effects of exemestane on bone and lipids in the ovariectomized rat (abstract). Breast Cancer Research and Treatment 69 224.
39. Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M & Maggi M 2001 Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49 267-277.
40. Greenlee RT, Hill-Harmon MB, Murray T & Thun M 2001. Cancer statistics. CA Cancer J Clin 51 15-36.
41. Guise TA 2000 Molecular mechanisms of osteolytic bone metastases. Cancer 88 2892-2898.
42. Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A'Hern R & Dowsett M 2001 Effects of the aromatase inhibitor letrazole in healthy postmenopausal women: rationale for prevention. Proceedings of the American Society of Clinical Oncology 20 3091.
43. Hatano T, Oishi Y, Furuta A, Iwamuro S & Tashiro K 2000 Incidence of bone fractures in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU International 86 449-452.
44. Headley JA, Theriault RL, Leblanc AD, Vassilopoulou-Sellin R & Hortobagyi GN 1998 Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Investigations 16 6-11.
45. Heidenreich A, Elert A & Hofmann R 2002 Ibandronate in the treatment of prostate cancer associated painful osseus metastases. Prostate Cancer and Prostatic Diseases 5 231-235.
46. Hiller BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT & Pfister DG 2000a American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology expert panel. Journal of Clinical Oncology 18 1378-1391.
47. Hillner BE, Weeks JC, Desch CE & Smith TJ 2000b Pamidronate on prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. Journal of Clinical Oncology 18 72-79.
48. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ & Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 15 2-12.
49. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M & Reitsma D 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine 335 1785-1791.
50. Hultborn R, Ryden S, Gunderson S, Holmberg E & Wallgren U-B 1996 Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial. Acta Oncologica 35 (Suppl 5) 73-74.
51. Jagdev SP, Croucher PI & Coleman RE 2000 Zoledronate induces apoptosis of breast cancer cells in vitro - evidence for additive and synergistic effects with taxol and tamoxifen. Proceedings of the American Society of Clinical Oncology 19 Abstract 2619.
52. Jagdev SP, Coleman RE, Shipman CM, Rostami HA & Croucher PI 2001a The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. British Journal of Cancer 84 1126-1134.
53. Jagdev SP, Croucher PI & Coleman RE 2001b The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases. European Journal of Cancer 37 S129.
54. Jagdev SP, Purohit OP, Heatley S, Herling C & Coleman RE 2001c Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Annals of Oncology 12 1433-1438.
55. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S & Spector T 1999 A high incidence of vertebral fractures in women with breast cancer. British Journal of Cancer 79 1179-1181.
56. Kostenuik PJ, WO, Suyama K & Singh G 1993 Increased growth rate and tumour burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Research 53 5452-5457.
57. Krempien B & Manegold C 1993 Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate C12MBP. Cancer 72 91-98.
58. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H & Mouridsen HT 1999 Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine 246 67-74.
59. Kylmala T, Tammela TL, Lindholm TS & Seppanen J 1994 The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Annales Chirurgiae et Gynaecologiae 83 316-319.
60. Kylmala T, Taube T, Tammela TL, Ristli L, Risteli J & Eloma A 1997 Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. British Journal of Cancer 76 939-942.
61. Lee MV, Fong EM, Singer FR & Guenette RS 2001 Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Research 61 2602-2608.
62. Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J & Lieberman JR 2002 Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Research 62 5564-5570.
63. Leuprolide Study Group 1984 Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New England Journal of Medicine 311 1281-1286.
64. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsman D & Seaman J 2002 The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Investigations 20 (Suppl 2) 45-54.
65. Mackie PS, Fisher JL, Zhou H & Choong PF 2001 Bisphosphonates regulate cell growth and gene expression in the UMR 106-101 clonal rat osteosarcoma cell line. British Journal of Cancer 84 951-958.
66. Magnetto S, Boissier S, Delmas PD & Clezardin P 1999 Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International Journal of Cancer 83 263-269.
67. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM & Tavernier C 1999 Bone mineral density in men treated with synthetic gonadotrophin- releasing hormone agonists for prostate carcinoma. Journal of Urology 161 1219-1222.
68. Major PP, Lortholary A, Hon J, Abdi T, Mills G, Mensen HD, Yunus F, Bell R, Body J, Fehling E & Seaman J 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology 19 558-567.
69. Miller KK & Klibanski A 1999 Amenorrheic bone loss. Journal of Clinical Endocrinology and Metabolism 84 1775-1783.
70. Mincey BA 2003 Osteoporosis in women with breast cancer. Breast Cancer 5 53-57.
71. Mundy GR 1999 Bone Remodelling and Its Disorders, edn 2. Martin Dunitz: London.
72. Mundy GR, Yoneda T & Hiraga T 2001 Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Seminars in Oncology 28 35-44.
73. National Cancer Institute of Canada Clinical Trials Group The influence of letrazole on bone mineral density in women with primary breast cancer completing five or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA 1 7.
74. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA & Simons JW 1995 Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine 1 944-949.
75. Parkin DM, Bray FI & Devesa SS 2001 Cancer burden in the year 2000. The global picture. 37 S4-S66.
76. Paterson AHG, Powles TJ, Kanis JA, McCloskey EV, Hanson J & Ashley S 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology 11 59-65.
77. Pelger RC, Hamdy NA, Zwinderman AH, Lycklama A, Nijeholt AA & Papapoulous SE 1998 Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22 403-408.
78. Pfeilschifter J & Diel IJ 2000 Osteoporosis due to cancer treatment: pathogenesis and management. Journal of Clinical Oncology 18 1570-1593.
79. Plunkett TA & Rubens RD 2003 Bisphosphonate therapy for patients with breast carcinoma: who to treat and when to stop. Cancer 97 (Suppl 3) 854-858.
80. Powles TJ, Hickish T, Kanis JA, Tidy A & Ashley S 1996 Effects of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology 14 78-84.
81. Powles TJ, McCloskey E, Paterson AH, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenquist K & Kanis J 1998 Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. Journal of the National Cancer Institute 90 704-708.
82. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenquist K, Smith-Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J & Pylkkanen L 2002 Randomised, placebo-controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology 20 3219-3224.
83. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body J-J & Meunier P 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine 346 653-661.
84. Riebeling C, Forsea AM, Raisova M, Orfaos CE & Geilen CC 2002 The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. British Journal of Cancer 87 366-371.
85. Rogers MJ, Brown RJ, Hodkin V, Blackburn GM, Russell RG & Watts DJ 1996 Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochemical and Biophysical Research Communications 224 863-869.
86. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman, SP, Monkkonen J & Frith JC 2000 Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 2961-2978.
87. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL & Ambros Y 2001 Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer Journal 7 377-387.
88. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen B-L & Seaman JJ 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomized, double-blind, multicenter, comparative trial. Cancer 98 1735-1744.
89. Russell RG & Rogers MJ 1999 Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 97-106.
90. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA & Chen B 2002 Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: a randomized, placebo-controlled trial. Journal of the National Cancer Institute 94 1458-1468.
91. Saarto T, Blomquist C, Valimaki M, Makela P, Sarna S & Elomaa I 1997 Chemical castration induced by adjuvant cyclophospamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. Journal of Clinical Oncology 15 1341-1347.
92. Saarto T, Blomqvist C, Virkkunen P & Elomaa I 2001 Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of randomised controlled trial. Journal of Clinical Oncology 19 10-17.
93. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V & Tonini G 2002 Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clinical Cancer Research 8 1080-1084.
94. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR & Yoneda T 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research 55 3551-3557.
95. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y & Matsumura T 1998 Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastass in nude mice. International Journal of Cancer 77 279-285.
96. Seeman E 1999 The structural basis of bone fragility in men. Bone 25 143-147.
97. Senaratne SG, Pirianov G, Mansi JL, Arnett TR & Colston KW 2000 Bisphosphonates induce apoptosis in human breast cancer cell lines. British Journal of Cancer 82 1459-1468.
98. Shapiro CL, Manola J & Leboff M 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of Clinical Oncology 19 3306-3311.
99. Shipman CM & Croucher PI 2003 Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Research 63 912-916.
100. Shipman CM, Croucher PI, Russell RG, Helfrich MH & Rogers MJ 1998 The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Research 58 5294-5297.
101. Smith JA 1989 Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. Journal of Urology 141 85-87.
102. Smith MR 2003 Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treatment Reviews 29 211-218.
103. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfield DA, Kantoff PW & Finkelstein JS 2001 Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. New England Journal of Medicine 345 948-955.
104. Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S & Zinner N 2003 Randomised controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for non metastatic prostate cancer. Journal of Urology 169 2008-2012.
105. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W & van Valen F 2001 The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drug 12 459-465.
106. Spelsberg TC, Subramaniam M, Riggs BL et al. 1999. The actions and interactions of sex steroids and growth factors/ cytokines on the skeleton. Molecular Endocrinology 13 819-828.
107. Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst E, Bandman U, Borck L, Englund G & Selin L 1997 The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Research 17 4717-4721.
108. Takuwa, Y, Masaki T & Yamashita K 1990 The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochemical and Biophysical Research Communications 170 998-1005.
109. Tassone P, Forciniti S, Galea, E, Morrone G, Turco MC, Martinelli V, Tagliaferri P & Venuta S 2000 Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14 841-844.
110. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi, P & Sorsa T 1999 MMP inhibition and down regulation by bisphosphonates. Annals of the New York Academy of Sciences 878 453-465.
111. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M & Reitsman DJ 1999 Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. Journal of Clinical Oncology 17 846-854.
112. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ & Gillespie MT 1999 Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140 4451-4458.
113. Townsend MF, Sanders WH, Northway RO & Graham SD 1997 Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79 545-550.
114. Tripathy D, Lazarev A, Lichinitser MR, Decker D, McLachlan SA & Budde M 2002 Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastases. Proceedings of the American Society of Clinial Oncology 21 176 Abstract 45a.
115. Tripathy D, Body J-J, Diel IJ & Bergstrom B for the Bondronat Study Group 2003. Oral daily ibandronate: efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer. Proceedings of the American Society of Clinial Oncology 22 46 Abstract 185.
116. Turner RT, Riggs BL & Spelsberg TC 1994 Skeletal effects of oestrogen. Endocrine Reviews 15 275-300.
117. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C & Papapoulos S 1996 Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Journal of Clinical Investigation 98 698-705.
118. Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harins HI, Vermey P, Elte JW, Neijt JP & Beex LV 1987 Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet ii 983-985.
119. Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papuoulos SE & Sleeboom HP 1993 Palliative bone treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology 11 491-498.
120. Vinholes JJ, Purohit OP, Abbey ME, Eastell R & Coleman RE 1997 Relationship between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Annals of Oncology 8 1243-1250.
121. Virtanen S, Vaananen HK, Harkonen PL & Lakkakorpi PT 2002 Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Research 62 2708-2714.
122. Wheeler DL, Van der Griend RA, Wronski TJ, Miller GJ, Keith EE & Graves JE 1995 The short-term and long-term effects of methotrexate on the rat skeleton. Bone 16 215-221.
123. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L & Foidart JM 2002 Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. Journal of Pharmacology and Experimental Therapeutics 302 1055-1061.
124. World Health Organization Technical Report 1994 Assessment of fracture risk and its applications to screening for postmenopausal osteoporosis: report of a WHO study group.